Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Open Access Articles
Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
, 2022; 22(6): 530 - 536Xue Wang, Nanlin Hu, Lina Cui, Yiran Si, Jian Yue, Fangchao Zheng, Yikun Kang and Peng Yuan*
Promotion of Cervical Cancer Cell Proliferation by miR-130b Expression Level Changes and Inhibition of its Apoptosis by Targeting CDKN1A Gene
, 2022; 22(2): 153 - 168Yanli Wang, Lei Yang, Caihong Fan, Hong Mu*, Munan Han, Tao Liu, Lili Xie and Qiang Gao
Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators
, 2021; 21(4): 353 - 359Stefanie Rauscher, Richard Greil and Roland Geisberger*
Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting
, 2021; 21(1): 70 - 79Prakash Lingasamy, Anett-Hildegard Laarmann and Tambet Teesalu *
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL
, 2020; 20(10): 811 - 817Sven Nilsson, Alexander Stein, Christian Rolfo, Anne L. Kranich, Julia Mann, Konstantinos Papadimitriou, Susann Theile, Stefanie Amberg and Carsten Bokemeyer*
The Roles of Alternative Splicing in Tumor-immune Cell Interactions
, 2020; 20(10): 729 - 740Yue Wang, Honglei Zhang*, Baowei Jiao*, Jianyun Nie*, Xiyin Li, Wenhuan Wang and Hairui Wang
Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
, 2019; 19(1): 74 - 80Peng Liu, Hailin Tang, Jiali Wu, Xingsheng Qiu, Yanan Kong, Lijuan Zhang, Xinhua Xie* and Xiangsheng Xiao*
Role of MicroRNAs in Treatment Response in Prostate Cancer
, 2018; 18(10): 929 - 944Anshuli Razdan, Paul de Souza* and Tara Laurine Roberts
Noxa: Role in Cancer Pathogenesis and Treatment
, 2018; 18(10): 914 - 928Rami Z. Morsi, Rouba Hage-Sleiman, Hadile Kobeissy and Ghassan Dbaibo*
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
, 2017; 17(7): 637 - 649Sarah L. Sammons, Donna L. Topping and Kimberly L. Blackwell*
Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer
, 2016; 16(4): 346 - 356Xue-Qing Hu, Yang Sun, Eric Lau, Ming Zhao and Shi-Bing Su
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Webmaster Contact: info@benthamscience.net